Home » Stocks » CRNX

Crinetics Pharmaceuticals, Inc. (CRNX)

Stock Price: $17.62 USD -0.04 (-0.23%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Market Cap 654.31M
Revenue (ttm) n/a
Net Income (ttm) -79.35M
Shares Out 33.01M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $17.62
Previous Close $17.66
Change ($) -0.04
Change (%) -0.23%
Day's Open 17.73
Day's Range 17.10 - 18.12
Day's Volume 143,217
52-Week Range 11.61 - 21.64

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option -

1 month ago - GlobeNewsWire

SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel...

1 month ago - GlobeNewsWire

Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021

2 months ago - GlobeNewsWire

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel...

3 months ago - GlobeNewsWire

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel...

3 months ago - GlobeNewsWire

Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting

3 months ago - GlobeNewsWire

Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ET Webcast and conference call to take place on Tuesday, March 30, 2021 at 4:30 p.m. ET

4 months ago - GlobeNewsWire

Oral and Late-breaker Presentations Selected on the Company's ACTH Antagonist and Congenital HI Programs Oral and Late-breaker Presentations Selected on the Company's ACTH Antagonist and Congenital HI P...

4 months ago - GlobeNewsWire

- Details of New Paltusotine Tablet Formulation to be Unveiled -

4 months ago - GlobeNewsWire

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel...

5 months ago - GlobeNewsWire

Phase 1 study is designed to provide clinical proof-of-concept by taking advantage of established methods in endocrinology Phase 1 study is designed to provide clinical proof-of-concept by taking advant...

5 months ago - GlobeNewsWire

- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 -

6 months ago - GlobeNewsWire

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Ple...

8 months ago - GlobeNewsWire

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel ...

8 months ago - GlobeNewsWire

Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time Webinar Being Held on Friday, November 20th @ 11:00 am Eastern Time

8 months ago - GlobeNewsWire

Crinetics Pharmaceuticals (CRNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trial s of oral paltusotine for the treatment of acromegaly

8 months ago - GlobeNewsWire

ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy  

9 months ago - GlobeNewsWire

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of nov...

10 months ago - GlobeNewsWire

SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of nov...

10 months ago - GlobeNewsWire

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invi...

10 months ago - GlobeNewsWire

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of nov...

10 months ago - GlobeNewsWire

Crinetics Pharmaceuticals (CRNX) is a clinical stage company focused on in house synthesis of novel molecules for rare endocrine diseases.

10 months ago - Seeking Alpha

Paltusotine received Orphan Drug Designation for the treatment of acromegaly

11 months ago - GlobeNewsWire

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of nove...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Crinetics Pharmaceuticals, Inc. (CRNX).

1 year ago - Zacks Investment Research

28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commercially avail...

1 year ago - GlobeNewsWire

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...

1 year ago - GlobeNewsWire

Crinetics Pharmaceuticals (CRNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly

1 year ago - GlobeNewsWire

SAN DIEGO, April 17, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of nov...

1 year ago - GlobeNewsWire

Crinetics Pharmaceuticals, Inc. (CRNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of nov...

1 year ago - GlobeNewsWire

SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of nov...

1 year ago - GlobeNewsWire

SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of no...

1 year ago - GlobeNewsWire

The coronavirus induced sell-off has created a number of attractive buying opportunities.

Other stocks mentioned: ABBV, AGEN, APHA, BCEL, BCYC, BMY, CPRX ...
1 year ago - The Motley Fool

Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

These relative newcomers to the landscape of publicly-traded biotech stocks could be big winners for early shareholders.

Other stocks mentioned: BCEL
1 year ago - The Motley Fool

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -11.11% and 51.65%, respectively, for the quarter ended September 2019.

1 year ago - Zacks Investment Research

Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of nov...

1 year ago - GlobeNewsWire

Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

1 year ago - Zacks Investment Research

SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of nov...

1 year ago - GlobeNewsWire

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -13.33% and -100.00%, respectively, for the quarter ended June 2019.

1 year ago - Zacks Investment Research

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developin... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 2018
CEO
R. Scott Struthers
Employees
93
Stock Exchange
NASDAQ
Ticker Symbol
CRNX
Full Company Profile

Financial Performance

In 2020, CRNX's revenue was $71,000, a decrease of -94.05% compared to the previous year's $1.19 million. Losses were -$73.81 million, 46.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is 37.50, which is an increase of 112.83% from the latest price.

Price Target
$37.50
(112.83% upside)
Analyst Consensus: Buy